Changes in Metabolite Ratios after Treatment with Rivastigmine in Alzheimer???s Disease

References

Page 1

	Year	Citations
Clinical diagnosis of Alzheimer's disease Guy M. McKhann, David A. Drachman, Marshall Folstein, Neurology	1984	27.8K
Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. B L Miller, Rex Moats, Truda Shonk, Radiology Healthy SubjectsProton Mr SpectroscopyElderly PatientsNeurochemical BiomarkersAlzheimer's Disease	1993	361
Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Truda Shonk, Rex Moats, P Gifford, Radiology	1995	300
MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD Clifford R. Jack, M Słomkowski, S. Gracon, Neurology	2003	294
Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer’s Disease Kousik Krishnan, H. Cecil Charles, P. Murali Doraiswamy, American Journal of Psychiatry	2003	286
<sup>1</sup> H MR spectroscopy in common dementias Kejal Kantarci, Ronald C. Petersen, Bradley F. Boeve, Neurology	2004	263
Does Donepezil Treatment Slow the Progression of Hippocampal Atrophy in Patients With Alzheimer’s Disease? Mamoru Hashimoto, Hiroaki Kazui, K. Matsumoto, American Journal of Psychiatry	2005	243
Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy Małgorzata Marjańska, Geoffrey L. Curran, Thomas M. Wengenack, Proceedings of the National Academy of Sciences	2005	198
[Cognocitive mini-test (a simple practical test to detect intellectual changes in medical patients)]. António Lobo, J Ezquerra, Gómez Burgada F, PubMed NeuropsychologyPsychiatryMedicineDifferential DiagnosisDiagnostic Criterion	1979	197
Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging D. J. Meyrhoff, S. MacKay, Jean‐Marc Constans, Annals of Neurology	1994	161

Page 1